Westchester Capital Management (New York)’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Westchester Capital Management (New York)’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,266,444	Closed	-$60.8M	–	216
2020 Q1	$60.8M	Buy	1,266,444 +1,155,128	+1,038%	+$53.7M	2.3%	17
2019 Q4	$5.22M	Buy	+111,316	New	+$4.92M	0.18%	73

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Westchester Capital Management (New York)'s RARX Position: Q2 2020 in Review

Westchester Capital Management (New York) sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 1,266,444 shares — an estimated $60.8M sold.

Westchester Capital Management (New York) first reported a position in RARX in Q4 2019 and held it in 2 quarters. The position peaked at $60.8M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Westchester Capital Management (New York) reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Westchester Capital Management (New York) sold 1,266,444 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $60.8M.
Westchester Capital Management (New York) first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
Westchester Capital Management (New York)'s Ra Pharmaceuticals, Inc. Common Stock position peaked at $60.8M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Westchester Capital Management (New York)'s 13F filing for Q2 2020, filed 14 Aug 2020.